AZ-UNIVERSAL-ELECTRONICS
1.5.2020 22:17:07 CEST | Business Wire | Press release
Universal Electronics Inc. (UEI) (NASDAQ: UEIC), the global leader in universal control and sensing technologies for the smart home, has received five 2020 Red Dot Awards , one of the most prestigious international design awards, in the Product Design category. Products from UEI’s consumer brand, One For All , won four of the five awards.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200501005501/en/
The award-winning products were designed by UEI’s design team in the Netherlands, part of the global Designovation team which creates product designs based on user insights and innovative technology. Led by Rex Xu, Director of Design and User Experience, the team in the Netherlands works closely with UEI’s design offices in the U.S. and Hong Kong to ensure all products truly reflect global trends in design and technology.
“Winning five Red Dot Awards is a true honor and a testament to our design team’s exceptional talent,” said Xu. “Design is one of UEI’s key differentiators and we always create our designs with the user experience in mind. The team works under clear guiding principles of our successful Designovation formula which creates honest product designs based on true consumer insights applying the latest technology and design trends.”
Two of One For All’s TV stands were recognized with 2020 Red Dot Awards:
The Tripod Universal TV Stand fits televisions up to 65 inches, can swivel a true 360 degrees and blends into any corner with natural chestnut or oak wooden legs for a modern look.
The One For All Falcon Universal TV Stand supports televisions up to 70 inches and is designed to accommodate soundbars, streaming boxes and game consoles connected to the television. With its fabric skinned storage cover at the back of the television, cables are completely out of sight.
One For All also won two Red Dot awards for its market-leading digital TV antennas:
The Amplified Indoor TV Antenna features leading reception technology in a beautiful fabric skinned housing. With its homey design, it can hang on the wall, stand or lie flat while allowing for maximum channel coverage.
The darker colored Amplified Indoor TV Antenna offers a stylish look and unique signal level indicator that blends into the fabric housing. This ensures optimal signal and maximum number of available channels.
The fifth Red Dot Award is for UEI’s Kita premium Android TV voice remote control specifically designed for service providers with advanced video services that want a simplified user experience. In addition to supporting voice control and dedicated streaming app keys, this remote control features adaptive control which interacts with the television and only shows users the keys they need. It uses rechargeable technology in a slim housing, saving multiple batteries over the life of the product.
For more information about how to purchase these award-winning products, contact info@uei.com .
In 2019 One For All won Red Dot Awards for its Amplified Indoor Ball Design Antenna and One For All FLUX Gas Spring TV Wall Mount. With origins dating back to 1955, the Red Dot is established internationally as one of the most sought-after quality marks for outstanding design with annual competitions for Product Design, Brands and Communication, and Design Concept. Red Dot Award submissions are evaluated by a jury of independent designers, design professors and journalists.
All trademarks appearing herein are the property of their respective owners.
One For All is a registered trademark of Universal Electronics Inc.
About Universal Electronics Inc.
Founded in 1986, Universal Electronics Inc. (NASDAQ: UEIC) is the global leader in universal control and sensing technologies for the smart home. The company designs, develops, manufactures and ships over 500 innovative products that are used by the world’s leading brands in the consumer electronics, subscription broadcast, security, home automation, hospitality and climate control markets. For more information, visit www.uei.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200501005501/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom